TP53 and prostate cancer: In prostate cancer, ANRIL overexpression was shown to recruit CBX7 (a Polycomb Repressive Complex 1 protein) to the INK4 locus to enhance methylation and decrease the expression of all genes contained within this locus, including ARF, which may suggest increased P53 degradation [336].